<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="riboflavin-tn" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">riboflavin-tn</book-part-id>
      <title-group>
        <title>Riboflavin Transporter Deficiency Neuronopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Manole</surname>
            <given-names>Andreea</given-names>
          </name>
          <degrees>BSc</degrees>
          <email>andreea.manole.13@ucl.ac.uk</email>
          <aff>MRC Centre for Neuromuscular Diseases<break/>Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square<break/>London, United Kingdom</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Houlden</surname>
            <given-names>Henry</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>h.houlden@ucl.ac.uk</email>
          <aff>Department of Molecular Neurosciences and MRC Centre for Neuromuscular Diseases<break/>Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square<break/>London, United Kingdom</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2015-06-11" date-type="created">
          <day>11</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="rcdp" document-type="chapter">Rhizomelic Chondrodysplasia Punctata Type 1</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="rbs" document-type="chapter">Roberts Syndrome</related-object>
      <abstract id="riboflavin-tn.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical description</title>
          <p>Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting and breathing problems due to paralysis of the diaphragm), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy). Onset is usually in infancy or in childhood before age eight years; however, on occasion individuals with genetically proven disease present in the third decade. When untreated, most infants with riboflavin transporter deficiency rapidly become ventilator dependent and die in the first years of life. In the majority of affected individuals the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other manifestations varies but is usually one to two years. In some individuals an inter-current event, usually an injury or infection, appears to precipitate the initial manifestations or worsen existing findings.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of riboflavin transporter deficiency neuronopathy is based on clinical, neurophysiologic, neuroimaging, and laboratory findings as well as the identification of biallelic pathogenic variants in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> High-dose oral supplementation of riboflavin between 10 mg and 50 mg/kg/day improves symptoms and signs on clinical examination, improves objective testing (vital capacity, brain stem evoked potentials, nerve conduction studies), and normalizes acylcarnitine levels. The optimal dose is as yet unknown.</p>
          <p>Because oral riboflavin supplementation is effective (and possibly life saving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by molecular genetic testing.</p>
          <p>Supportive care includes: respiratory support; physiotherapy to avoid contractures; occupational therapy to support activities of daily living; orthotics for limb and trunk bracing; speech and language therapy to avoid choking and respiratory problems; wheel chair as needed; low vision aids as needed; routine management of scoliosis to avoid long-term respiratory problems; and routine management of depression.</p>
          <p><italic toggle="yes">Surveillance:</italic> At three months and six months after initiation of riboflavin supplementation: follow-up physical and neurologic examinations, and measurement of blood riboflavin/FAD/FMN and acylcarnitine analysis. Thereafter, follow up should be biannual in older individuals and more frequent in younger children.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Dietary restriction of riboflavin.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> When the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants in the family are known, it is appropriate to perform molecular genetic testing on the older and younger sibs of an affected individual to identify as early as possible those who would benefit from early treatment with riboflavin supplementation and monitoring for potential complications of the disorder.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Females who have riboflavin transporter neuronopathy or are heterozygous for a pathogenic variant in <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> should have riboflavin supplements before and during pregnancy and when breast feeding to avoid inducing riboflavin deficiency in the baby.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Riboflavin transporter deficiency neuronopathy is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic heterozygote (carrier), and a 25% chance of being unaffected and not a carrier. Heterozygote (carrier) testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="riboflavin-tn.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="riboflavin-tn.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_riboflavin-tn.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Riboflavin Transporter Deficiency Neuronopathy: Included Disorders</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_riboflavin-tn.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Brown-Vialetto-Van Laere (BVVL) syndrome</p>
                    </list-item>
                    <list-item>
                      <p>Fazio-Londe syndrome</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="riboflavin-tn.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="riboflavin-tn.Diagnosis">
        <title>Diagnosis</title>
        <p>Riboflavin transporter deficiency neuronopathy is a phenotypic continuum of motor, sensory, and cranial nerve neuronopathy caused by mutation of either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> and including the following previously recognized disorders: Brown-Vialetto-Van Laere (BVVL) syndrome; Fazio-Londe syndrome, which is similar to BVVL syndrome but lacks cranial nerve VIII involvement (i.e., deafness) [<xref ref-type="bibr" rid="riboflavin-tn.REF.fazio.1892.327">Fazio 1892</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.londe.1894.212">Londe 1894</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
        <sec id="riboflavin-tn.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Riboflavin transporter deficiency neuronopathy should be suspected in individuals with the following clinical, neurophysiologic, neuroimaging, and laboratory findings of motor, sensory, and cranial nerve neuronopathy [<xref ref-type="bibr" rid="riboflavin-tn.REF.gomez.1962.317">Gomez et al 1962</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.alexander.1976.66">Alexander et al 1976</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.mcshane.1992.1889">McShane et al 1992</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.sathasivam.2000.277">Sathasivam et al 2000</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.sathasivam.2008.9">Sathasivam 2008</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.horvath.2012.679">Horvath 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>].</p>
          <p><bold>Clinical features</bold> consist of progressive childhood onset* of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Motor</bold> neuronopathy:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Affecting upper limbs more than lower limbs, resulting in weakness, involving proximal and distal limb musculature, often with severe distal wasting. Deep tendon reflexes are consistently absent.</p>
                </list-item>
                <list-item>
                  <p>Resulting in axial weakness, manifest as severe trunk and neck weakness requiring trunk bracing and difficulty with holding the head up</p>
                </list-item>
                <list-item>
                  <p>Resulting in paralysis of the diaphragm which can result in respiratory insufficiency</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Sensory</bold> neuronopathy manifesting as gait ataxia</p>
            </list-item>
            <list-item>
              <p><bold>Cranial</bold> neuronopathy</p>
              <list list-type="bullet">
                <list-item>
                  <p>Typically affecting cranial nerves II (optic atrophy variably associated nystagmus), VIII (sensorineural hearing loss), IX and X (bulbar palsy), and XII (tongue fasciculations, weakness, and atrophy)</p>
                </list-item>
                <list-item>
                  <p>Occasionally affecting cranial nerves III (ptosis) and VII (facial weakness)</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Cognition is usually preserved.</p>
          <p><bold>*</bold>Note: Onset age range is a few months to early teenage years, and very rarely in adulthood.</p>
          <p>
            <bold>Neurophysiologic studies</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Electromyogram (EMG) shows chronic partial denervation.</p>
            </list-item>
            <list-item>
              <p>Nerve conduction studies (NCS) show a sensory&#x0003e;motor axonal neuronopathy. Motor nerve conduction velocities are usually normal.</p>
            </list-item>
            <list-item>
              <p>Sensory nerve action potentials (SNAP) are often absent.</p>
            </list-item>
            <list-item>
              <p>Visual evoked potentials (VEP) are frequently abnormal.</p>
            </list-item>
            <list-item>
              <p>Brain stem audiometry evoked response (BAER) has universally shown sensorineural deafness.</p>
            </list-item>
            <list-item>
              <p>EEG (electroencephalogram) may show an excess of theta activity or slow waves [<xref ref-type="bibr" rid="riboflavin-tn.REF.rosemberg.1982.84">Rosemberg et al 1982</xref>].</p>
            </list-item>
          </list>
          <p><bold>Brain MRI</bold> is usually normal; however, in a small number of affected individuals cerebellar atrophy and hyperintense areas in the brain stem and cerebral peduncles are observed.</p>
          <p><bold>Laboratory findings.</bold> Acylcarnitine profile in blood is abnormal with accumulation of short and medium-chain (and sometimes long-chain) acylcarnitines in some but not all individuals with genetically proven riboflavin transporter deficiency neuronopathy [<xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
          <p>It should be noted that even in children diagnosed in the first months of life with abnormal acylcarnitine profiles, newborn screening bloodspots demonstrated normal acylcarnitine profiles, probably due to sufficient maternal riboflavin supply to the unborn infant [<xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>].</p>
        </sec>
        <sec id="riboflavin-tn.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of riboflavin transporter deficiency neuronopathy is based on the clinical, neurophysiologic, neuroimaging, and laboratory findings described above as well as the identification of biallelic pathogenic variants in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> on molecular genetic testing (<xref ref-type="table" rid="riboflavin-tn.T.summary_of_molecular_gen">Table 1</xref>).</p>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel.</bold></p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Simultaneous sequence analysis of <italic toggle="yes">SLC52A2</italic> and <italic toggle="yes">SLC52A3</italic> is performed first, followed by gene-targeted deletion/duplication analysis if only one pathogenic variant is found in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic>. Note: Although subtle differences are observed in the phenotype of individuals with mutation of <italic toggle="yes">SLC52A2</italic> compared with the phenotype of individuals with mutation of <italic toggle="yes">SLC52A3</italic>, the phenotypes are sufficiently similar that both genes should be tested at the same time rather than sequentially.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">SLC52A2</italic> and <italic toggle="yes">SLC52A3</italic> as well as other genes of interest selected on potentially similar clinical presentations (see <xref ref-type="sec" rid="riboflavin-tn.Differential_Diagnosis">Differential Diagnosis</xref>) may also be used. Multi-gene panels have been developed to include <italic toggle="yes">SLC52A1</italic>, <italic toggle="yes">SLC52A2</italic>, <italic toggle="yes">SLC52A3</italic>, <italic toggle="yes">ETFA</italic>, <italic toggle="yes">ETFB,</italic>
<italic toggle="yes">ETFDH</italic>, <italic toggle="yes">IGHMBP, ALSIN</italic>, <italic toggle="yes">ALADIN</italic>, and <italic toggle="yes">UBQLN1</italic> [<xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.angelini.2015">Angelini 2015</xref>]. Note: The genes included in multi-gene panels vary by laboratory and over time.</p>
            </list-item>
          </list>
          <p>Note: Because oral riboflavin supplementation is effective (and possibly lifesaving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by molecular genetic testing.</p>
          <table-wrap id="riboflavin-tn.T.summary_of_molecular_gen" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Riboflavin Transporter Deficiency Neuronopathy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_2" rowspan="2" valign="top" align="left" scope="col" colspan="1" headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_2">Proportion of Riboflavin Transporter Deficiency Neuronopathy Attributed to Mutation of This Gene</th>
                  <th id="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3" id="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></th>
                  <th headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3" id="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SLC52A2</italic>
                  </td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~30%</td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">13/13 probands&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">No large deletions/duplications&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SLC52A3</italic>
                  </td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~70%</td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">18/18 probands&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">No large deletions/duplications&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_1_3 hd_h_riboflavin-tn.T.summary_of_molecular_gen_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="riboflavin-tn.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="riboflavin-tn" object-id="riboflavin-tn.Genetic_Counseling">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="riboflavin-tn.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.4">
                <label>4. </label>
                <p>All variants have been detected using Sanger sequencing or next generation exome sequencing and then Sanger sequencing confirmation.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.6">
                <label>6. </label>
                <p><xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</xref> provide the most extensive screening of <italic toggle="yes">SLC52A2</italic>: 13 of 72 probands with cranial neuronopathy, sensorimotor neuronopathy, and respiratory insufficiency were found to have biallelic pathogenic variants. Other smaller case series and individual families have been reported as well.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.7">
                <label>7. </label>
                <p>No large deletions/duplications identified using chromosome microarray analysis (CMA) [Manole et al, unpublished data]</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.8">
                <label>8. </label>
                <p>Manole [unpublished data] provides the most extensive screening of <italic toggle="yes">SLC52A3</italic>: Eighteen of 116 individuals with cranial neuropathy and sensorimotor neuropathy &#x000b1; respiratory insufficiency were found to have biallelic pathogenic variants. Other smaller series and individual families have been reported as well.</p>
              </fn>
              <fn id="riboflavin-tn.TF.1.9">
                <label>9. </label>
                <p>A number of individuals with cranial neuropathy and sensorimotor neuropathy &#x000b1; respiratory insufficiency have not had pathogenic variants identified using exome sequencing and Sanger sequencing [Manole unpublished data]. In a number of individuals large deletions/duplications in <italic toggle="yes">SLC52A1</italic>, <italic toggle="yes">SLC52A2,</italic> and <italic toggle="yes">SLC52A3</italic> (see <xref ref-type="sec" rid="riboflavin-tn.Molecular_Genetics">Molecular Genetics</xref>) were excluded using CMA [Manole et al, unpublished data].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="riboflavin-tn.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="riboflavin-tn.Clinical_Description">
          <title>Clinical Description</title>
          <p>Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting [<xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>] and breathing problems), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy).</p>
          <p>Onset is usually in infancy or in childhood before age eight years, although on occasion individuals with genetically proven disease present in the third decade.</p>
          <p>Typically, after a symptom-free first few weeks (or in some cases months) of life, infants become floppy with failure to thrive and rapidly developing respiratory insufficiency due to paralysis of the diaphragm, followed (in order of appearance) by:</p>
          <list list-type="bullet">
            <list-item>
              <p>Infantile- or early childhood-onset nystagmus</p>
            </list-item>
            <list-item>
              <p>Early childhood-onset sensory (gait) ataxia</p>
            </list-item>
            <list-item>
              <p>Childhood onset sensorineural deafness</p>
            </list-item>
            <list-item>
              <p>Weakness and atrophy of the upper limbs (first distally then proximally)</p>
            </list-item>
            <list-item>
              <p>Weakness of neck extensors and later trunk muscles</p>
            </list-item>
            <list-item>
              <p>Tongue fasciculations and atrophy with increased swallowing problems</p>
            </list-item>
            <list-item>
              <p>Respiratory insufficiency due to muscle weakness</p>
            </list-item>
          </list>
          <p>Other initial presenting features can include stridor, slurring of speech, and facial weakness. Visual problems due to optic atrophy are common [<xref ref-type="bibr" rid="riboflavin-tn.REF.gomez.1962.317">Gomez et al 1962</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.alexander.1976.66">Alexander et al 1976</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.summers.1987.440">Summers et al 1987</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.abarbanel.1991.349">Abarbanel et al 1991</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.nemoto.2005">Nemoto et al 2005</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.descatha.2006.187">Descatha et al 2006</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.malheiros.2007.32">Malheiros et al 2007</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.miao.2007.214">Miao et al 2007</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.dakhil.2010.397">Dakhil et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.srour.2014.775">Srour et al 2014</xref>].</p>
          <p>Untreated, most infants diagnosed with riboflavin transporter deficiency neuronopathy rapidly become ventilator dependent (often for some years at home or on intensive care units) and most die before age 12 years [<xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>].</p>
          <p>In the majority of affected individuals presenting after infancy the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other symptoms varies but is usually one to two years. Very rarely affected individuals do not develop deafness, and sometimes deafness appears later in the disease course.</p>
          <p>With improved disease management and riboflavin treatment, life span is likely to increase; however, treatment with riboflavin has only been reported since 2010 [<xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.horvath.2012.679">Horvath 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>].</p>
          <p>In some individuals an inter-current event, usually an injury or infection, appears to precipitate the initial symptoms or worsen existing symptoms [<xref ref-type="bibr" rid="riboflavin-tn.REF.gallai.1981.259">Gallai et al 1981</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.voudris.2002.732">Voudris et al 2002</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>].</p>
          <p>Other neurologic features can include: occasional sensory involvement, retinitis pigmentosa and macular hyperpigmentation, autonomic dysfunction, and epilepsy.</p>
          <p>The phenotypes caused by mutation of <italic toggle="yes">SLC52A2</italic> are difficult to differentiate from those caused by mutation of <italic toggle="yes">SLC52A3</italic>; however, in individuals with mutation of <italic toggle="yes">SLC52A2</italic> early-onset weakness in the upper limbs and neck is almost invariable &#x02013; in contrast to those with mutation of <italic toggle="yes">SLC52A3</italic> or genetically unclassified Brown-Vialetto-Van Laere (BVVL) syndrome, in whom the onset of weakness is often more generalized [<xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
          <p><bold>Other neurophysiologic studies.</bold> Electrocardiogram showed incomplete right bundle branch block in one individual [<xref ref-type="bibr" rid="riboflavin-tn.REF.m_garban_.2000.117">M&#x000e9;garban&#x000e9; et al 2000</xref>].</p>
          <p>Sleep studies demonstrated predominantly central sleep apnea with minimal obstructive sleep apnea in one individual [<xref ref-type="bibr" rid="riboflavin-tn.REF.miao.2007.214">Miao et al 2007</xref>].</p>
          <p>CSF protein is often raised but &#x0003c;1 g/dL [<xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
          <p><bold>Pathology.</bold> Few pathologic descriptions of riboflavin transporter deficiency neuronopathy are available. The authors know of only one pathologic description of an archival genetically proven case; however, findings were similar to those in individuals who had not undergone molecular genetic testing [<xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</xref>]. There was usually neuronal injury and loss in cranial nerve nuclei III, V, VI and lower cranial nerve nuclei (VII &#x02013; XII); depletion of spinal anterior horn cells, lateral columns, and pyramidal tracts; and degeneration of cerebellar Purkinje cells and basal ganglia [<xref ref-type="bibr" rid="riboflavin-tn.REF.rosemberg.1982.84">Rosemberg et al 1982</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.summers.1987.440">Summers et al 1987</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.abarbanel.1991.349">Abarbanel et al 1991</xref>].</p>
        </sec>
        <sec id="riboflavin-tn.GenotypePhenotype_Correlat">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date no genotype-phenotype correlations have been identified in <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> [Author, personal observation]<italic toggle="yes">.</italic></p>
        </sec>
        <sec id="riboflavin-tn.Nomenclature">
          <title>Nomenclature</title>
          <p>Childhood-onset progressive bulbar palsy developing in the first and second decade of life was traditionally separated into Brown-Vialetto-Van Laere (BVVL) syndrome and Fazio-Londe syndrome (a BVVL-like syndrome without deafness). It is now known that Brown-Vialetto-Van Laere syndrome and Fazio-Londe syndrome are caused by biallelic pathogenic variants in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic>.</p>
          <p><xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al [2012]</xref> and <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</xref> have proposed new BVVL syndrome nomenclature to clarify the specific mechanism of disease: riboflavin transporter deficiency neuronopathy, type 2 (corresponding with <italic toggle="yes">SLC52A2</italic>-associated disease) and riboflavin transporter deficiency neuronopathy, type 3 (corresponding with <italic toggle="yes">SLC52A3</italic>-associated disease).</p>
          <p>BVVL syndrome was first reported in 1894 by Charles Brown as an &#x02018;infantile&#x02019; form of ALS with associated hearing loss [<xref ref-type="bibr" rid="riboflavin-tn.REF.brown.1894.707">Brown 1894</xref>]. The male index case manifested an acute onset of bulbar weakness, hearing loss and respiratory insufficiency at age 12 years, with rapid progression of symptoms and later involvement of the upper limbs as well as &#x02018;general arrest of development and emaciation&#x02019;. The report of three siblings with pontobulbar paralysis and associated hearing loss by Dr. Ernesto Vialetto in 1936 [<xref ref-type="bibr" rid="riboflavin-tn.REF.vialetto.1936.1">Vialetto 1936</xref>] followed by the report of three sisters with similar clinical features by MJ Van Laere in 1966 resulted in the term BVVL syndrome being used to describe this pontobulbar palsy [<xref ref-type="bibr" rid="riboflavin-tn.REF.van_laere.1966.289">Van Laere 1966</xref>].</p>
          <p>Hereditary progressive bulbar palsy without deafness has also been described and referred to as Fazio-Londe syndrome [<xref ref-type="bibr" rid="riboflavin-tn.REF.fazio.1892.327">Fazio 1892</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.londe.1894.212">Londe 1894</xref>]; it was initially described in a mother and her son and later reported in two brothers with a more rapidly progressive syndrome.</p>
        </sec>
        <sec id="riboflavin-tn.Prevalence">
          <title>Prevalence</title>
          <p>Although riboflavin transporter deficiency neuronopathy is a relatively rare condition, it appears to be more prevalent than previously thought given the advent of molecular genetic testing, which has improved diagnostic capabilities [<xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>]. Based on the number of individuals screened for pathogenic variants in <italic toggle="yes">SLC52A2</italic> and <italic toggle="yes">SLC52A3</italic>, the authors estimate 70 new diagnoses worldwide per year; however, it is difficult to provide a precise figure at this stage [Manole et al, unpublished data based on genetic referral numbers].</p>
        </sec>
      </sec>
      <sec id="riboflavin-tn.Genetically_Related_Alleli">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic>.</p>
        <p>Sporadic tumors (including esophageal squamous cell carcinomas) occurring as single tumors in the absence of any other findings of this syndrome frequently harbor somatic pathogenic variants in <italic toggle="yes">SLC52A3</italic> that are <bold>not</bold> present in the germline; thus, predisposition to these tumors is not heritable. For more details see Molecular Genetics, <xref ref-type="sec" rid="riboflavin-tn.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</xref>.</p>
      </sec>
      <sec id="riboflavin-tn.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Multiple acyl-CoA dehydrogenase deficiency (MADD)</bold> (also known as glutaric acidemia II or glutaric aciduria II) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231680">231680</ext-link>) can be caused by biallelic pathogenic variants in at least three different genes: <italic toggle="yes">ETFA</italic>, <italic toggle="yes">ETFB</italic>, and <italic toggle="yes">ETFDH</italic>. These genes are all involved in electron transfer in the mitochondrial respiratory chain [<xref ref-type="bibr" rid="riboflavin-tn.REF.olsen.2007.2045">Olsen et al 2007</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.law.2009.95">Law et al 2009</xref>].</p>
        <p>The clinical features of MADD are grouped into three types:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal-onset form with congenital anomalies (type I)</p>
          </list-item>
          <list-item>
            <p>Neonatal-onset form without congenital anomalies (type II)</p>
          </list-item>
          <list-item>
            <p>Late-onset form (type III)</p>
          </list-item>
        </list>
        <p>The neonatal-onset forms, which are usually fatal, are characterized by severe hypoketotic hypoglycemia, metabolic acidosis, multisystem involvement, and excretion of large amounts of fatty acid- and amino acid-derived metabolites.</p>
        <p>Symptoms and age at presentation of late-onset MADD are highly variable and characterized by proximal muscle weakness, recurrent episodes of lethargy, vomiting, hypoglycemia, metabolic acidosis, and hepatomegaly often preceded by metabolic stress [<xref ref-type="bibr" rid="riboflavin-tn.REF.law.2009.95">Law et al 2009</xref>]. Neuronopathy is not observed in MADD.</p>
        <p>In MADD acylcarnitine analysis usually reveals increased concentrations of several short-chain, medium-chain, and long-chain acylcarnitines. In individuals with late-onset disease, abnormalities may be mild, atypical, or only detectable during decompensation.</p>
        <p><bold>Spinal muscular atrophy with respiratory distress type 1 (SMARD1)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/604320">604320</ext-link>) is an &#x0201c;SMA plus&#x0201d; syndrome caused by biallelic pathogenic variants in <italic toggle="yes">IGHMBP2</italic> (encoding immunoglobulin mu binding protein 2), usually leading to early-onset severe axonal polyneuronopathy with distal muscle and lower-limb weakness and respiratory failure due to diaphragmatic paralysis. Infantile onset is most common. There may also be autonomic involvement, pneumonia, and hypotonia; deafness has not been described [<xref ref-type="bibr" rid="riboflavin-tn.REF.yiu.2008.930">Yiu et al 2008</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter"><bold>Spinal muscular atrophy</bold></related-object> (caused by mutation of <italic toggle="yes">SMN1</italic>) mostly involves the anterior horn cells of motor neurons; however, some affected individuals may have peripheral motor and sensory nerve involvement [<xref ref-type="bibr" rid="riboflavin-tn.REF.yiu.2008.930">Yiu et al 2008</xref>].</p>
        <p><bold>Nathalie syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/255990">255990</ext-link>) has no lower cranial nerve signs but includes deafness and weakness in addition to spinal muscular atrophy (SMA), cataracts, hypogonadism, and cardiac conduction defects [<xref ref-type="bibr" rid="riboflavin-tn.REF.cremers.1975.330">Cremers et al 1975</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.sathasivam.2008.9">Sathasivam 2008</xref>].</p>
        <p><bold>Madras motor neuron disease (MMND)</bold> (also referred to as Madras pattern motor neuron disease), a rare young age-onset progressive neuromuscular disease with a relatively benign course, has predominantly been observed in southern India. Multiple cranial nerve palsies particularly involve the seventh and ninth to 12th cranial nerves. Hearing impairment is present in all patients; optic atrophy is present in some. Although the majority are simplex cases (i.e., a single occurrence in a family), a few familial cases have been reported. The etiology is unknown; mutation of <italic toggle="yes">SLC52A2</italic> and <italic toggle="yes">SLC52A3</italic> as well as <italic toggle="yes">C9orf72</italic> has been excluded [<xref ref-type="bibr" rid="riboflavin-tn.REF.valmikinathan.1973.753">Valmikinathan et al 1973</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.shankar.2000.428">Shankar et al 2000</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.nalini.2013.119">Nalini et al 2013</xref>].</p>
        <p><bold>Facial onset sensory motor neuronopathy (FOSMN)</bold> is a recently described under-recognized, rare, slowly progressive bulbar onset motor and sensory neuronopathy [<xref ref-type="bibr" rid="riboflavin-tn.REF.vucic.2012.73">Vucic et al 2012</xref>]. Although there are marked similarities to classic bulbar-onset motor neuron disease, FOSMN differs clinically by the striking facial-onset sensory deficits with subsequent development of motor deficits, slow evolution in a rostral-caudal direction, and a much better prognosis. The finding of TDP-43 pathology in an individual with FOSMN suggests an overlap with motor neuron disease, although further evidence and studies are needed. The heterozygous variant Asp90Ala was identified in <italic toggle="yes">SOD1</italic> in a patient with FOSMN [<xref ref-type="bibr" rid="riboflavin-tn.REF.dalla_bella.2014.1009">Dalla Bella et al 2014</xref>]; its role in causation of MND is unclear.</p>
        <p><bold>Allgrove or triple A syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231550">231550</ext-link>), caused by mutation of <italic toggle="yes">ALADIN,</italic> is a rare autosomal recessive disorder that has prominent bulbar features, although achalasia, alacrima, and adrenal problems are the primary manifestations [<xref ref-type="bibr" rid="riboflavin-tn.REF.houlden.2002.2681">Houlden et al 2002</xref>]. Of note, affected individuals also have an abnormal, small fissured tongue similar to that of individuals with amyotrophic lateral sclerosis (ALS) [<xref ref-type="bibr" rid="riboflavin-tn.REF.houlden.2009.1366">Houlden 2009</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.manole.2014.506">Manole et al 2014</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic lateral sclerosis</related-object> (ALS) is characterized by adult-onset degeneration of motor neurons in the corticospinal tract and brain stem, and the anterior horn cells of the spinal cord. Patients have upper motor neuron (UMN) and lower motor neuron (LMN) limb signs with progressive muscle weakness and wasting, fasciculations, and spasticity. Patients often die of respiratory paralysis [<xref ref-type="bibr" rid="riboflavin-tn.REF.hardiman.2011.639">Hardiman et al 2011</xref>]. BVVL has been described as an autosomal recessive juvenile form of ALS since both BVVL and ALS have bulbar and LMN involvement. BVVL differs from ALS in that BVVL includes deafness and has an earlier age of onset and a more irregular disease course; UMN limb signs are not invariably present [<xref ref-type="bibr" rid="riboflavin-tn.REF.hardiman.2011.639">Hardiman et al 2011</xref>].</p>
        <p>Of note, mutation of <italic toggle="yes">UBQLN2</italic> (encoding ubiquilin 2<italic toggle="yes">)</italic> has been identified as a rare cause of ALS; a recent study has identified a heterozygous variant in a related gene (<italic toggle="yes">UBQLN1</italic>) previously linked to neurodegeneration in an individual with BVVL and an atypical early-onset ALS with bulbar palsy and hearing loss. Although the pathogenicity of this variant remains uncertain, this finding highlights the overlap of the BVVL and ALS phenotypes [<xref ref-type="bibr" rid="riboflavin-tn.REF.gonz_lezp_rez.2012.391">Gonz&#x000e1;lez-P&#x000e9;rez et al 2012</xref>].</p>
      </sec>
      <sec id="riboflavin-tn.Management_1">
        <title>Management</title>
        <sec id="riboflavin-tn.Evaluations_Following_Init">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with riboflavin transporter deficiency neuronopathy, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Evaluation by a neuromuscular specialist with attention to possible weakness, sensory loss, gait disturbance, and need for bracing</p>
            </list-item>
            <list-item>
              <p>Sleep study and pulmonary consultation</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation with attention to visual acuity and possible optic atrophy</p>
            </list-item>
            <list-item>
              <p>Audiologic assessment</p>
            </list-item>
            <list-item>
              <p>Other consultations depending on clinical problems; for example, orthopedic consultation if scoliosis is present or psychiatry consultation if depression is present</p>
            </list-item>
            <list-item>
              <p>Rehabilitation assessments: physiotherapy, occupational therapy, orthotics, speech and language therapy, wheel chair clinic</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist/genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="riboflavin-tn.Treatment_of_Manifestation">
          <title>Treatment of Manifestations</title>
          <sec id="riboflavin-tn.Medications">
            <title>Medications</title>
            <p><bold>High dose supplementation</bold>
<bold>of</bold>
<bold>riboflavin.</bold> Because oral riboflavin supplementation is effective (and possibly life saving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by molecular genetic testing.</p>
            <p>High-dose supplementation of riboflavin between 10 mg and 50 mg/kg/day has been effective in patients with genetically proven riboflavin transporter deficiency neuronopathy and also in some patients in whom the genetic basis of riboflavin transporter deficiency neuronopathy has not been established.</p>
            <p>Although no formal placebo control trial has been conducted and the longest course of riboflavin supplementation has been 36 months, riboflavin supplementation: improves symptoms and signs on clinical examination; improves objective testing (vital capacity, brain stem evoked potentials, nerve conduction studies), and normalizes acylcarnitine levels [<xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
            <p>Before initiating riboflavin supplementation, perform the assessments in <xref ref-type="sec" rid="riboflavin-tn.Evaluations_Following_Init">Evaluations Following Initial Diagnosis</xref>.</p>
            <p>Oral riboflavin supplementation should be given in gradually increasing doses in order to establish the optimum dose:</p>
            <list list-type="bullet">
              <list-item>
                <p>Riboflavin 10 mg/kg per day in 3 doses for 1 month</p>
              </list-item>
              <list-item>
                <p>Riboflavin 20 mg/kg per day in 3 doses for 1 month</p>
              </list-item>
              <list-item>
                <p>Riboflavin 30 mg/kg per day in 3 doses for 1 month</p>
              </list-item>
              <list-item>
                <p>Riboflavin 40 mg/kg per day in 3 doses for 1 month</p>
              </list-item>
              <list-item>
                <p>Riboflavin 50 mg/kg per day in 3 doses for 1 month</p>
              </list-item>
            </list>
            <p>Note: Some patients are on doses up to 70 mg/kg/day.</p>
            <p>Side effects, problems, or deterioration at any point require discussion with the treating clinician.</p>
            <p>See <xref ref-type="sec" rid="riboflavin-tn.Surveillance">Surveillance</xref> for recommended follow up of individuals treated with riboflavin supplementation.</p>
            <p>Note: Treatments attempted before the basis of riboflavin transporter deficiency neuronopathy was known have included the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Intravenous immunoglobulin (IVIG) has been tried in a number of patients with reports of improvement as well as reports of no or non-sustained response [<xref ref-type="bibr" rid="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p>Some patients have reported additional improvement with other multivitamins and coenzyme Q<sub>10</sub>.</p>
              </list-item>
            </list>
          </sec>
          <sec id="riboflavin-tn.Supportive_Care">
            <title>Supportive Care</title>
            <p>The following are appropriate:</p>
            <list list-type="bullet">
              <list-item>
                <p>Respiratory support</p>
              </list-item>
              <list-item>
                <p>Physiotherapy to avoid contractures</p>
              </list-item>
              <list-item>
                <p>Occupational therapy for support in activities of daily living</p>
              </list-item>
              <list-item>
                <p>Orthotics for limb and trunk bracing</p>
              </list-item>
              <list-item>
                <p>Hearing aids and appropriate educational intervention for those with sensorineural hearing loss</p>
              </list-item>
              <list-item>
                <p>Speech and language therapy to avoid choking and respiratory problems</p>
              </list-item>
              <list-item>
                <p>Wheel chair as needed</p>
              </list-item>
              <list-item>
                <p>Low vision aids for those with decreased visual acuity</p>
              </list-item>
              <list-item>
                <p>Routine management of scoliosis to avoid long term respiratory problems</p>
              </list-item>
              <list-item>
                <p>Routine management of depression</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="riboflavin-tn.Surveillance">
          <title>Surveillance</title>
          <p>At three months and six months after initiation of riboflavin supplementation, recommended follow up is:</p>
          <list list-type="bullet">
            <list-item>
              <p>General examination</p>
            </list-item>
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>Discussion of any problems with riboflavin supplementation</p>
            </list-item>
            <list-item>
              <p>Ideally, obtaining a blood sample for riboflavin/FAD/FMN, acylcarnitine analysis (if previous evaluation demonstrated abnormalities) to determine if these levels are normalizing</p>
            </list-item>
          </list>
          <p>After one year of riboflavin supplementation, repeat examination/investigations as detailed in <xref ref-type="sec" rid="riboflavin-tn.Evaluations_Following_Init">Evaluation Following Initial Diagnosis</xref> except for consultation with a medical geneticist/genetic counselor.</p>
        </sec>
        <sec id="riboflavin-tn.AgentsCircumstances_to_Avo">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid dietary restriction of riboflavin. If not possible to avoid dietary restriction, provide riboflavin supplements.</p>
        </sec>
        <sec id="riboflavin-tn.Evaluation_of_Relatives_at">
          <title>Evaluation of Relatives at Risk</title>
          <p>When the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants in the family are known, it is appropriate to perform molecular genetic testing on the older and younger sibs of a proband with riboflavin transporter deficiency neuronopathy to identify as early as possible those with biallelic pathogenic variants who would benefit from early treatment with riboflavin supplementation and monitoring for potential complications of the disorder.</p>
          <p>See <xref ref-type="sec" rid="riboflavin-tn.Related_Genetic_Counseling">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="riboflavin-tn.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Females who have riboflavin transporter deficiency neuronopathy with biallelic pathogenic variants in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> should take riboflavin supplements before and during pregnancy and when breast feeding to avoid inducing riboflavin deficiency in the fetus and infant. Recommended doses during pregnancy are 10 mg/kg/day.</p>
          <p>Few studies have evaluated for adverse fetal outcome after excessive maternal riboflavin intake during pregnancy. Riboflavin deficiency during pregnancy, however, has been associated with an increased risk of maternal preeclampsia and preterm delivery [<xref ref-type="bibr" rid="riboflavin-tn.REF.wacker.2000.38">Wacker et al 2000</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.carmichael.2013.579">Carmichael et al 2013</xref>].</p>
          <p>Note: Although no data are available, the authors recommend a diet rich in riboflavin during pregnancy for females who are heterozygous for a pathogenic variant in either <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> as it is unknown if they are at increased risk of developing symptoms due to an increased demand for riboflavin during pregnancy.</p>
        </sec>
        <sec id="riboflavin-tn.Therapies_Under_Investigat">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="riboflavin-tn.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="riboflavin-tn.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Riboflavin transporter deficiency neuronopathy is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="riboflavin-tn.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">SLC52A2</italic> or one <italic toggle="yes">SLC52A3</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Under normal dietary conditions carriers have no symptoms. Theoretically, carriers could have symptoms of riboflavin transporter deficiency neuronopathy if other conditions that lead to riboflavin depletion (e.g., dietary restriction, malnourishment, pregnancy, and/or illness) co-occur (see <xref ref-type="sec" rid="riboflavin-tn.Pregnancy_Management">Pregnancy Management</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Under normal dietary conditions carriers have no symptoms. Theoretically, carriers could have symptoms of riboflavin transporter deficiency neuronopathy if other conditions that lead to riboflavin depletion (e.g., dietary restriction, malnourishment, pregnancy, and/or illness) co-occur (see <xref ref-type="sec" rid="riboflavin-tn.Pregnancy_Management">Pregnancy Management</xref>).</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with riboflavin transporter deficiency neuronopathy are obligate heterozygotes (carriers) for an <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variant.</p>
        </sec>
        <sec id="riboflavin-tn.Carrier_Heterozygote_Detec">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="riboflavin-tn.Related_Genetic_Counseling">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="riboflavin-tn.Evaluation_of_Relatives_at">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="riboflavin-tn.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of the gene of interest or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">SLC52A2</italic> or <italic toggle="yes">SLC52A3</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="riboflavin-tn.Resources">
        <title>Resources</title>
      </sec>
      <sec id="riboflavin-tn.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="riboflavin-tn.Molecular_Genetic_Pathogen">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">SLC52A2</italic> and <italic toggle="yes">SLC52A3</italic> encode transmembrane proteins (hRFVT2 and hRFVT3, respectively) that mediate cellular uptake of riboflavin. The water-soluble vitamin riboflavin is converted to the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), and is essential for normal cellular functions. These coenzymes are essential in a number of cellular processes such as normal mitochondrial function.</p>
          <p>Although a third member of this gene family, <italic toggle="yes">SLC52A1</italic> encoding hRFVT1<italic toggle="yes">,</italic> has not been implicated directly in riboflavin transporter deficiency neuronopathy to date [<xref ref-type="bibr" rid="riboflavin-tn.REF.chiong.2007.109">Chiong et al 2007</xref>; <xref ref-type="bibr" rid="riboflavin-tn.REF.ho.2011.e1976">Ho et al 2011</xref>; Manole, unpublished data on 116 cases], a <italic toggle="yes">de novo</italic> heterozygous <italic toggle="yes">SLC52A1</italic> deletion of exons 2 and 3 was identified in the mother of a child with multiple neurologic and systemic abnormalities [<xref ref-type="bibr" rid="riboflavin-tn.REF.ho.2011.e1976">Ho et al 2011</xref>].</p>
          <p>Early-onset weakness in the upper limbs and neck is almost invariably seen in persons with biallelic pathogenic variants in <italic toggle="yes">SLC52A2</italic> in contrast to those with biallelic pathogenic variants in <italic toggle="yes">SLC52A3</italic> or genetically unclassified BVVL syndrome, in whom the onset of weakness is often more generalized [<xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>]. This observation could be explained by the tissue distribution of the transporters: hRFVT1 and hRFVT3 are mainly localized in the small intestinal epithelial cells and may be complimentary. In particular, hRFVT3 may transport sufficient riboflavin to prevent profound RF deficiency when there is haploinsufficiency of hRFVT1. Expression of hRFVT2 is primarily in the brain, explaining the normal circulating levels of flavins, but transport of riboflavin into the brain is impaired in hRFVT2 deficiency resulting in abnormal metabolism [<xref ref-type="bibr" rid="riboflavin-tn.REF.yonezawa.2013.693">Yonezawa &#x00026; Inui 2013</xref>].</p>
          <sec id="riboflavin-tn.SLC52A2">
            <title>
              <italic toggle="yes">SLC52A2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC52A2</italic> produces a 1900-bp transcript, four coding exons of 445 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_024531.4">NM_024531.4</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="riboflavin-tn" object-id="riboflavin-tn.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> Pathogenic variants in <italic toggle="yes">SLC52A2</italic> are distributed throughout the gene in regions encoding transmembrane, intracellular, and extracellular loops [<xref ref-type="bibr" rid="riboflavin-tn.REF.dezfouli.2012.613">Dezfouli et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>]. Only nonsynonymous pathogenic variants in the homozygous or compound heterozygous state have been reported in <italic toggle="yes">SLC52A2</italic> to date [<xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</xref>, Spagnoli et al 2013].</p>
            <p>An <italic toggle="yes">SLC52A2</italic> founder pathogenic variant has been described (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_024531.4">NM_024531.4</ext-link>:c.916G&#x0003e;A; p.Gly306Arg) in the Lebanese population [<xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.srour.2014.775">Srour et al 2014</xref>].</p>
            <p>No large insertions or deletions have been found to date [<xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
            <p>See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="riboflavin-tn-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf) for information on pathogenic variants in <italic toggle="yes">SLC52A2</italic>.</p>
            <p>
              <bold>In vitro analysis of specific <italic toggle="yes">SLC52A2</italic> pathogenic variants</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Reduced riboflavin uptake was observed when the <italic toggle="yes">SLC52A2</italic> p.Leu123Pro and p.Leu339Pro pathogenic variants were expressed in HEK293 cells [<xref ref-type="bibr" rid="riboflavin-tn.REF.haack.2012.943">Haack et al 2012</xref>].</p>
              </list-item>
              <list-item>
                <p>Riboflavin uptake was reduced in fibroblasts of a patient with the <italic toggle="yes">SLC52A2</italic> pathogenic variants p.[Gly419Ser];[Ser52Phe]; residual activity was 29% of controls when cells were grown in low riboflavin medium (0.4 nM) [<xref ref-type="bibr" rid="riboflavin-tn.REF.ciccolella.2013.104">Ciccolella et al 2013</xref>]. In this patient, <italic toggle="yes">SLC52A2</italic> mRNA expression was significantly reduced (45%), while <italic toggle="yes">SLC52A1</italic> mRNA expression was unaffected; however, the protein levels of both <italic toggle="yes">RFVT1</italic> and <italic toggle="yes">RFVT2</italic> were undetectable. In vitro studies of the parents&#x02019; fibroblasts suggested that the p.Ser52Phe variant may impair <italic toggle="yes">SLC52A2</italic> mRNA stability, while the p.Gly419Ser variant may affect protein function.</p>
              </list-item>
              <list-item>
                <p><xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</xref> determined the <sup>3</sup>H-riboflavin transport activities and protein expression in HEK293 cells transiently expressing the following <italic toggle="yes">SLC52A2</italic> variants: p.Trp31Ser, p.Gln234Stop, p.Ala284Asp, p.Tyr305Cys, p.Gly306Arg, p.Leu312Pro, and p.Leu339Pro. Cells expressing the variants displayed the greatest reduction in riboflavin uptake. The expression levels of all <italic toggle="yes">SLC52A2</italic> mutants were reduced, except the p.Trp31Ser mutant for which expression remained near wild-type levels in the plasma membrane [<xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
              </list-item>
            </list>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">SLC52A2</italic> encodes solute carrier family 52, riboflavin transporter, member 2 (also known as riboflavin transporter 2 [hRFVT2]) comprising 445 amino acid residues.</p>
            <p><bold>Abnormal gene product.</bold> See <xref ref-type="sec" rid="riboflavin-tn.Molecular_Genetic_Pathogen">Molecular Genetic Pathogenesis</xref>; see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="riboflavin-tn-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf) for a summary of in vitro expression studies of <italic toggle="yes">SLC52A2</italic> pathogenic variants.</p>
          </sec>
          <sec id="riboflavin-tn.SLC52A3">
            <title>
              <italic toggle="yes">SLC52A3</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC52A3</italic> produces a 2716-bp transcript, four coding exons of 469 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_033409.3">NM_033409.3</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="riboflavin-tn" object-id="riboflavin-tn.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants</bold>. Pathogenic variants in <italic toggle="yes">SLC52A3</italic> are distributed throughout the gene in regions encoding the transmembrane, intracellular, and extracellular loops [<xref ref-type="bibr" rid="riboflavin-tn.REF.dezfouli.2012.613">Dezfouli et al 2012</xref>, Foley et al2014].</p>
            <p>Thus far, nonsynonymous, stop-gain, frameshift, and splice-site altering pathogenic variants have been identified in the homozygous or compound heterozygous state [<xref ref-type="bibr" rid="riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</xref>]. No large insertions or deletions have been identified to date [<xref ref-type="bibr" rid="riboflavin-tn.REF.green.2010.485">Green et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.foley.2014.44">Foley et al 2014</xref>].</p>
            <p>See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="riboflavin-tn-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf) for pathogenic variants in <italic toggle="yes">SLC52A3</italic>.</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">SLC52A3</italic> encodes solute carrier family 52, riboflavin transporter, member 3 (also known as riboflavin transporter 3 [hRFVT3]) comprising 469 amino acid residues.</p>
            <p><bold>Abnormal gene product.</bold> The following <italic toggle="yes">SLC52A3</italic> pathogenic variants have been shown to cause reduced riboflavin uptake: Trp17Arg, Pro28Thr, Glu36Lys, Glu71Lys, and Arg132Trp. Confocal imaging of these mutant proteins showed that they were retained within the endoplasmic reticulum as opposed to the cell surface [<xref ref-type="bibr" rid="riboflavin-tn.REF.nabokina.2012.652">Nabokina et al 2012</xref>].</p>
          </sec>
          <sec id="riboflavin-tn.Cancer_and_Benign_Tumors">
            <title>Cancer and Benign Tumors</title>
            <p>Genome-wide association studies (GWAS) have shown that sporadic esophageal squamous cell carcinomas are associated with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=13042395">rs13042395</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3746804">rs3746804</ext-link> in <italic toggle="yes">SLC52A3</italic> [<xref ref-type="bibr" rid="riboflavin-tn.REF.ji.2012.982">Ji et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.palmer.2012.541">Palmer et al 2012</xref>, <xref ref-type="bibr" rid="riboflavin-tn.REF.piao.2014.798">Piao et al 2014</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="riboflavin-tn.References">
        <title>References</title>
        <sec id="riboflavin-tn.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="riboflavin-tn.Literature_Cited.reflist0">
            <ref id="riboflavin-tn.REF.abarbanel.1991.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abarbanel</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashby</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquez-Julio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>KR</given-names>
                  </name>
                </person-group>
                <article-title>Bulbo-pontine paralysis with deafness: the Vialetto-Van Laere syndrome.</article-title>
                <source>Can J Neurol Sci.</source>
                <year>1991</year>
                <volume>18</volume>
                <fpage>349</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">1913372</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.alexander.1976.66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emery</surname>
                    <given-names>ES</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Koerner</surname>
                    <given-names>FC</given-names>
                  </name>
                </person-group>
                <article-title>Progressive bulbar paresis in childhood.</article-title>
                <source>Arch Neurol.</source>
                <year>1976</year>
                <volume>33</volume>
                <fpage>66</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">1247398</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.angelini.2015">
              <mixed-citation publication-type="other">Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 2015;1852:615-21.</mixed-citation>
            </ref>
            <ref id="riboflavin-tn.REF.bandettini_di_poggio.2014.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bandettini Di Poggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monti Bragadin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doria-Lamba</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cereda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pardini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roccatagliata</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schenone</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome: clinical and neuroradiological findings of a genetically proven patient.</article-title>
                <source>Amyotroph Lateral Scler Frontotemporal Degener.</source>
                <year>2014</year>
                <volume>15</volume>
                <fpage>141</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">24079556</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.bosch.2011.159">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeling</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ijlst</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knoester</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Pol</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroomer</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2011</year>
                <volume>34</volume>
                <fpage>159</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">21110228</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.bosch.2012.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroek</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeling</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ijlst</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>83</fpage>
                <pub-id pub-id-type="pmid">23107375</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.brown.1894.707">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>CH</given-names>
                  </name>
                </person-group>
                <article-title>Infantile amyotrophic lateral sclerosis of the family type.</article-title>
                <source>J Nerv Ment Dis.</source>
                <year>1894</year>
                <volume>21</volume>
                <fpage>707</fpage>
                <lpage>16</lpage>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.carmichael.2013.579">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carmichael</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>GM</given-names>
                  </name>
                  <collab>National Birth Defects Prevention Study</collab>
                </person-group>
                <article-title>Maternal dietary nutrient intake and risk of preterm delivery.</article-title>
                <source>Am J Perinatol.</source>
                <year>2013</year>
                <volume>30</volume>
                <fpage>579</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">23208764</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.chiong.2007.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chiong</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Transient multiple acyl-CoA dehydrogenation deficiency in a newborn female caused by maternal riboflavin deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>109</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">17689999</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.ciccolella.2013.104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ciccolella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catteruccia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tozzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizza</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrozzo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nizzardo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronchi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations.</article-title>
                <source>J Med Genet.</source>
                <year>2013</year>
                <volume>50</volume>
                <fpage>104</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23243084</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.cremers.1975.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ter Haar</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Rens</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <article-title>The Nathalie syndrome. A new hereditary syndrome.</article-title>
                <source>Clin Genet.</source>
                <year>1975</year>
                <volume>8</volume>
                <fpage>330</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">1204231</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.dakhil.2010.397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dakhil</surname>
                    <given-names>FO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensreiti</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zew</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <article-title>Pontobulbar palsy and sensorineural deafness (Brown-Vialetto-van Laere syndrome): the first case from Libya.</article-title>
                <source>Amyotroph Lateral Scler.</source>
                <year>2010</year>
                <volume>11</volume>
                <fpage>397</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20001484</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.dalla_bella.2014.1009">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dalla Bella</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigamonti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mantero</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morbin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saccucci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gellera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauria</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Heterozygous D90A-SOD1 mutation in a patient with facial onset sensory motor neuronopathy (FOSMN) syndrome: a bridge to amyotrophic lateral sclerosis.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2014</year>
                <volume>85</volume>
                <fpage>1009</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">24591457</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.descatha.2006.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Descatha</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goddet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aboab</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allary</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gergereau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Cardiac arrest in a patient with Brown-Vialetto-Van Laere syndrome.</article-title>
                <source>Amyotroph Lateral Scler.</source>
                <year>2006</year>
                <volume>7</volume>
                <fpage>187</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16963409</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.dezfouli.2012.613">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dezfouli</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yadegari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nafissi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elahi</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Four novel C20orf54 mutations identified in Brown-Vialetto-Van Laere syndrome patients.</article-title>
                <source>J Hum Genet.</source>
                <year>2012</year>
                <volume>57</volume>
                <fpage>613</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22718020</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.dipti.2005.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dipti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livingston</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aggarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crow</surname>
                    <given-names>YJ</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease.</article-title>
                <source>Brain Dev.</source>
                <year>2005</year>
                <volume>27</volume>
                <fpage>443</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16122634</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.fazio.1892.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fazio</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Ereditarieta della paralisi bulbare progressiva.</article-title>
                <source>Riforma Med.</source>
                <year>1892</year>
                <volume>8</volume>
                <fpage>327</fpage>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.foley.2014.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Foley</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menezes</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandraud</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Odaib</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrams</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yonezawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCullagh</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Megarbane</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antony</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broomfield</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Byrne</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olpin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppenheim</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hargreaves</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Land</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>MX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gold</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phadke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGarvey</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouvrier</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.</article-title>
                <source>Brain.</source>
                <year>2014</year>
                <volume>137</volume>
                <issue>Pt 1</issue>
                <fpage>44</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">24253200</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.gallai.1981.259">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallai</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hockaday</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppenheimer</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rushworth</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Ponto-bulbar palsy with deafness (Brown-Vialetto-Van Laere syndrome).</article-title>
                <source>J Neurol Sci.</source>
                <year>1981</year>
                <volume>50</volume>
                <fpage>259</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">7229669</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.gomez.1962.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gomez</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clermont</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Progressive bulbar paralysis in childhood (Fazio-Londe's disease). Report of a case with pathologic evidence of nuclear atrophy.</article-title>
                <source>Arch Neurol.</source>
                <year>1962</year>
                <volume>6</volume>
                <fpage>317</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">13900073</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.gonz_lezp_rez.2012.391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez-P&#x000e9;rez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chian</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sapp</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanzi</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertram</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenna-Yasek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not typical ALS.</article-title>
                <source>Neurobiol Dis.</source>
                <year>2012</year>
                <volume>48</volume>
                <fpage>391</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22766032</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.green.2010.485">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiseman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crow</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riphagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheridan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josifova</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>86</volume>
                <fpage>485</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20206331</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.haack.2012.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makowski</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hempel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tauer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahting</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimatsu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yonezawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>943</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22864630</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.hardiman.2011.639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hardiman</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiernan</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Clinical diagnosis and management of amyotrophic lateral sclerosis.</article-title>
                <source>Nat Rev Neurol.</source>
                <year>2011</year>
                <volume>7</volume>
                <fpage>639</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">21989247</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.ho.2011.e1976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yonezawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B.</article-title>
                <source>Hum Mutat.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>E1976</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">21089064</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.horvath.2012.679">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10).</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>679</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">22231380</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.houlden.2002.2681">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Carvalho</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blake</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathias</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic characterization of families with triple A (Allgrove) syndrome.</article-title>
                <source>Brain.</source>
                <year>2002</year>
                <volume>125</volume>
                <fpage>2681</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">12429595</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.houlden.2009.1366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>The small, spastic, and furrowed tongue of Allgrove syndrome.</article-title>
                <source>Neurology.</source>
                <year>2009</year>
                <volume>72</volume>
                <fpage>1366</fpage>
                <pub-id pub-id-type="pmid">19365062</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.ji.2012.982">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ji</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>JZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>ZB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>XQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>LD</given-names>
                  </name>
                </person-group>
                <article-title>The relationship between C20orf54 gene rs3746804 position single nucleotide polymorphism and susceptibility to esophageal squamous cell carcinoma</article-title>
                <source>Zhonghua Nei Ke Za Zhi.</source>
                <year>2012</year>
                <volume>51</volume>
                <fpage>982</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23327963</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.johnson.2012.2875">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Megarbane</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foley</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arepalli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandraud</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim&#x000f3;n-S&#x000e1;nchez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramzon</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease.</article-title>
                <source>Brain.</source>
                <year>2012</year>
                <volume>135</volume>
                <fpage>2875</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">22740598</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.johnson.2010.567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing in Brown-Vialetto-van Laere syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>87</volume>
                <fpage>567</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20920669</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.law.2009.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Law</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hui</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fung</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fok</surname>
                    <given-names>TF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <article-title>Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Clin Chim Acta.</source>
                <year>2009</year>
                <volume>404</volume>
                <fpage>95</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19265687</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.londe.1894.212">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Londe</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Paralysie bulbaire progressive infantile et familiale.</article-title>
                <source>Rev Med.</source>
                <year>1894</year>
                <volume>14</volume>
                <fpage>212</fpage>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.malheiros.2007.32">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malheiros</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camargos</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardoso</surname>
                    <given-names>FE</given-names>
                  </name>
                </person-group>
                <article-title>A Brazilian family with Brown-Vialetto-van Laere syndrome with autosomal recessive inheritance.</article-title>
                <source>Arq Neuropsiquiatr.</source>
                <year>2007</year>
                <volume>65</volume>
                <fpage>32</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17420823</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.manole.2014.506">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manole</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fratta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Recent advances in bulbar syndromes: genetic causes and disease mechanisms.</article-title>
                <source>Curr Opin Neurol.</source>
                <year>2014</year>
                <volume>27</volume>
                <fpage>506</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">25159929</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.mcshane.1992.1889">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McShane</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brett</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Progressive bulbar paralysis of childhood. A reappraisal of Fazio-Londe disease.</article-title>
                <source>Brain.</source>
                <year>1992</year>
                <volume>115</volume>
                <fpage>1889</fpage>
                <lpage>900</lpage>
                <pub-id pub-id-type="pmid">1486466</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.m_garban_.2000.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000e9;garban&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerres</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizkallah</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delague</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nabbout</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome in a large inbred Lebanese family: confirmation of autosomal recessive inheritance?</article-title>
                <source>Am J Med Genet.</source>
                <year>2000</year>
                <volume>92</volume>
                <fpage>117</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">10797435</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.miao.2007.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lei</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <article-title>Severe sleep-disordered breathing in a patient with Brown-Vialetto-Van Laere syndrome: polysomnographic findings.</article-title>
                <source>J Neurol Sci.</source>
                <year>2007</year>
                <volume>263</volume>
                <fpage>214</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17669429</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.nabokina.2012.652">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nabokina</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramanian</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <article-title>Effect of clinical mutations on functionality of the human riboflavin transporter-2 (hRFT-2).</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>105</volume>
                <fpage>652</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22273710</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.nalini.2013.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nalini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandraud</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mok</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Madras motor neuron disease (MMND) is distinct from the riboflavin transporter genetic defects that cause Brown-Vialetto-Van Laere syndrome.</article-title>
                <source>J Neurol Sci.</source>
                <year>2013</year>
                <month>Nov</month>
                <day>15</day>
                <volume>334</volume>
                <issue>1-2</issue>
                <fpage>119</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">24139842</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.nemoto.2005">
              <mixed-citation publication-type="other">Nemoto H, Konno S, Nomoto N, Wakata N, Kurihara T. A case of Brown-Vialetto-van Laere (BVVL) syndrome in Japan Rinsho Shinkeigaku. 2005;4:357-61.</mixed-citation>
            </ref>
            <ref id="riboflavin-tn.REF.olsen.2007.2045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olpin</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miedzybrodzka</surname>
                    <given-names>ZH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pourfarzam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frerman</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beresford</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornelius</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldfors</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <article-title>ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.</article-title>
                <source>Brain.</source>
                <year>2007</year>
                <volume>130</volume>
                <fpage>2045</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">17584774</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.palmer.2012.541">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochhead</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hold</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabkin</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chow</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lissowska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughan</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gammon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Omar</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <article-title>Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations.</article-title>
                <source>Eur J Cancer Prev.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>541</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22805490</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.piao.2014.798">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Piao</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kweon</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shim</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bae</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>YD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <article-title>Replication of results of genome-wide association studies on esophageal squamous cell carcinoma susceptibility loci in a Korean population.</article-title>
                <source>Dis Esophagus.</source>
                <year>2014</year>
                <volume>27</volume>
                <fpage>798</fpage>
                <lpage>801</lpage>
                <pub-id pub-id-type="pmid">24152165</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.rosemberg.1982.84">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosemberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lancellotti</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arita</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Castro</surname>
                    <given-names>NP</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Progressive bulbar paralysis of childhood (Fazio-Londe disease) with deafness. Case report with clinicopathologic correlation.</article-title>
                <source>Eur Neurol.</source>
                <year>1982</year>
                <volume>21</volume>
                <fpage>84</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7094955</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.sathasivam.2000.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sathasivam</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Sullivan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tilley</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome: case report and literature review.</article-title>
                <source>Amyotroph Lateral Scler Other Motor Neuron Disord.</source>
                <year>2000</year>
                <volume>1</volume>
                <fpage>277</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11465021</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.sathasivam.2008.9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sathasivam</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Brown-Vialetto-Van Laere syndrome.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2008</year>
                <volume>3</volume>
                <fpage>9</fpage>
                <pub-id pub-id-type="pmid">18416855</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.shankar.2000.428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shankar</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gourie-Devi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shankar</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasha</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santosh</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Pathology of Madras type of motor neuron disease (MMND)--a histological and immunohistochemical study.</article-title>
                <source>Acta Neuropathol.</source>
                <year>2000</year>
                <volume>99</volume>
                <fpage>428</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">10787043</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.spagnoli.2014.231">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spagnoli</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Pitt MC2, Rahman S3, de Sousa C4. Brown-Vialetto-van Laere syndrome: a riboflavin responsive neuronopathy of infancy with singular features.</article-title>
                <source>Eur J Paediatr Neurol.</source>
                <year>2014</year>
                <month>Mar</month>
                <volume>18</volume>
                <issue>2</issue>
                <fpage>231</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">24206674</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.srour.2014.775">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Srour</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Putorti</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartzentruber</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolduc</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shevell</surname>
                    <given-names>MI</given-names>
                  </name>
                  <collab>FORGE Canada Consortium</collab>
                </person-group>
                <article-title>Poulin C, O'ferrall E, Buhas D, Majewski J, Brais B. Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood.</article-title>
                <source>Muscle Nerve.</source>
                <year>2014</year>
                <volume>50</volume>
                <fpage>775</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24616084</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.summers.1987.440">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Summers</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swash</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingram</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Juvenile-onset bulbospinal muscular atrophy with deafness: Vialetta-van Laere syndrome or Madras-type motor neuron disease?</article-title>
                <source>J Neurol.</source>
                <year>1987</year>
                <volume>234</volume>
                <fpage>440</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">3655850</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.valmikinathan.1973.753">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valmikinathan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mascreen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meenakshisundaram</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snehalatha</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Biochemical aspects of motor neurone disease--Madras pattern.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>1973</year>
                <volume>36</volume>
                <fpage>753</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">4753872</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.van_laere.1966.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Laere</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Familial progressive chronic bulbo-pontine paralysis with deafness. A case of Klippel-Trenaunay syndrome in siblings of the same family. Diagnostic and genetic problems</article-title>
                <source>Rev Neurol (Paris)</source>
                <year>1966</year>
                <volume>115</volume>
                <fpage>289</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">5969547</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.vialetto.1936.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vialetto</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Contributo alla forma ereditaria della paralisi bulbare progressiva.</article-title>
                <source>Riv. Sper. di Fren.</source>
                <year>1936</year>
                <volume>40</volume>
                <fpage>1</fpage>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.voudris.2002.732">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voudris</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skardoutsou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vagiakou</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <article-title>Infantile progressive bulbar palsy with deafness.</article-title>
                <source>Brain Dev.</source>
                <year>2002</year>
                <volume>24</volume>
                <fpage>732</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12427524</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.vucic.2012.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vucic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedley-Whyte</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddel</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tisch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotschet</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cros</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiernan</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>FOSMN syndrome: novel insight into disease pathophysiology.</article-title>
                <source>Neurology.</source>
                <year>2012</year>
                <volume>79</volume>
                <fpage>73</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22722633</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.wacker.2000.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wacker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000fc;hauf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiwora</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Riboflavin deficiency and preeclampsia.</article-title>
                <source>Obstet Gynecol.</source>
                <year>2000</year>
                <volume>96</volume>
                <fpage>38</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">10862839</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.yiu.2008.930">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yiu</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornberg</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <article-title>Adolescent spinal muscular atrophy with calf hypertrophy and a deletion in the SMN gene.</article-title>
                <source>Muscle Nerve.</source>
                <year>2008</year>
                <volume>38</volume>
                <fpage>930</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">18508340</pub-id>
              </element-citation>
            </ref>
            <ref id="riboflavin-tn.REF.yonezawa.2013.693">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yonezawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52.</article-title>
                <source>Mol Aspects Med.</source>
                <year>2013</year>
                <volume>34</volume>
                <fpage>693</fpage>
                <lpage>701</lpage>
                <pub-id pub-id-type="pmid">23506902</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="riboflavin-tn.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="riboflavin-tn.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cnmd.ac.uk/">MRC Centre for Neuromuscular Diseases</ext-link>
          </p>
          <p>The authors are interested in neuromuscular diseases and channelopathies working on the genetics and also the functional aspects of these disorders.</p>
          <p>Emails for correspondence; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="andreea.manole.13@ucl.ac.uk">andreea.manole.13@ucl.ac.uk</email> and <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="h.houlden@ucl.ac.uk">h.houlden@ucl.ac.uk</email></p>
        </sec>
        <sec id="riboflavin-tn.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors would like to thank the patients and their families for their essential help with this work. This study was supported by the Medical Research Council UK, The Wellcome Trust and The Brain Research Trust (BRT). This study was also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).</p>
        </sec>
        <sec id="riboflavin-tn.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 June 2015 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>2 September 2014 (am) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
